Jie Sun1, Jingjing Zhao1, Zhenkun Yang1, Zhiyi Zhou2, Peihua Lu3. 1. Center of Clinical Research, Wuxi People's Hospital of Nanjing Medical University, Wuxi, China. 2. Department of Pathology, Wuxi People's Hospital of Nanjing Medical University, Wuxi, China. 3. Department of Medical Oncology, Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
Abstract
BACKGROUND: Gastric cancer (GC) is the most common type of gastrointestinal cancer, and has been studied extensively. However, resistance to chemotherapeutic agents has become a major problem, leading to treatment failure. This study aimed to investigate the molecular mechanisms mediating acquired resistance to cisplatin and fluorouracil (CF) combination-based chemotherapy in GC patients. METHODS: The microarray datasets (GSE14209, GSE30070) were downloaded from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) using the limma package in R/Bioconductor. Possible targets of the DEMs were predicted using miRWalk, and the putative miRNA-mRNA regulatory network was constructed using Cytoscape software. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) analyses were then conducted and visualized using the Search Tool for Retrieval of Interacting Genes (STRING) and Cytoscape. The prognostic value of hub genes was revealed by Kaplan-Meier Plotter. The causal relationships and interactions between proteins were displayed using DisNor. Finally, similarity analysis was conducted using the Connectivity Map (CMap) profiles to predict a group of small molecules in GC treatment. RESULTS: A total of 394 DEGs and 31 DEMs were identified after analysis of pre- and post-treatment samples of clinical responders to CF therapy. TM9SF4, hsa-miR-185-5p, and hsa-miR-145-5p were found to be critical in the miRNA-mRNA regulatory network. The DEGs were found to be mainly enriched in the processes of ribonucleoprotein complex assembly, catalytic activity acting on RNA, mitochondrial matrix, and thermogenesis. The DEMs were predominantly found to be involved in single-stranded RNA binding and endoplasmic reticulum lumen. HDAC5, DDX17, ILF3, and SDHC were identified as hub genes in the PPI network. Of these, HDAC5, DDX17, and ILF3 were found to be closely related to the overall survival of GC patients. DisNor identified the first neighbors of the key genes. Furthermore, CMap profiles predicted a group of small molecules, including several histone deacetylase inhibitors (HDACIs), menadione, and mibefradil, which could serve as promising therapeutic agents to reverse acquired resistance to CF therapy. CONCLUSIONS: Our findings reveal new targets and alternative therapies to overcome the acquired resistance of GC patients to CF treatment. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Gastric cancer (GC) is the most common type of gastrointestinal cancer, and has been studied extensively. However, resistance to chemotherapeutic agents has become a major problem, leading to treatment failure. This study aimed to investigate the molecular mechanisms mediating acquired resistance to cisplatin and fluorouracil (CF) combination-based chemotherapy in GC patients. METHODS: The microarray datasets (GSE14209, GSE30070) were downloaded from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) using the limma package in R/Bioconductor. Possible targets of the DEMs were predicted using miRWalk, and the putative miRNA-mRNA regulatory network was constructed using Cytoscape software. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) analyses were then conducted and visualized using the Search Tool for Retrieval of Interacting Genes (STRING) and Cytoscape. The prognostic value of hub genes was revealed by Kaplan-Meier Plotter. The causal relationships and interactions between proteins were displayed using DisNor. Finally, similarity analysis was conducted using the Connectivity Map (CMap) profiles to predict a group of small molecules in GC treatment. RESULTS: A total of 394 DEGs and 31 DEMs were identified after analysis of pre- and post-treatment samples of clinical responders to CF therapy. TM9SF4, hsa-miR-185-5p, and hsa-miR-145-5p were found to be critical in the miRNA-mRNA regulatory network. The DEGs were found to be mainly enriched in the processes of ribonucleoprotein complex assembly, catalytic activity acting on RNA, mitochondrial matrix, and thermogenesis. The DEMs were predominantly found to be involved in single-stranded RNA binding and endoplasmic reticulum lumen. HDAC5, DDX17, ILF3, and SDHC were identified as hub genes in the PPI network. Of these, HDAC5, DDX17, and ILF3 were found to be closely related to the overall survival of GC patients. DisNor identified the first neighbors of the key genes. Furthermore, CMap profiles predicted a group of small molecules, including several histone deacetylase inhibitors (HDACIs), menadione, and mibefradil, which could serve as promising therapeutic agents to reverse acquired resistance to CF therapy. CONCLUSIONS: Our findings reveal new targets and alternative therapies to overcome the acquired resistance of GC patients to CF treatment. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Gastric cancer (GC); acquired resistance; bioinformatics analysis; candidate small molecules
Authors: Min Ho Lee; Yoonjung Cho; Do Hyun Kim; Hyun Jun Woo; Ji Yeong Yang; Hye Jin Kwon; Min Ji Yeon; Min Park; Sa-Hyun Kim; Cheol Moon; Nagendran Tharmalingam; Tae Ue Kim; Jong-Bae Kim Journal: Am J Transl Res Date: 2016-12-15 Impact factor: 4.060
Authors: Kai Li; Chunfen Mo; Di Gong; Yan Chen; Zhao Huang; Yanyan Li; Jie Zhang; Lugang Huang; Yuan Li; Frances V Fuller-Pace; Ping Lin; Yuquan Wei Journal: Cancer Lett Date: 2017-03-01 Impact factor: 8.679
Authors: Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth Journal: Nucleic Acids Res Date: 2015-01-20 Impact factor: 16.971
Authors: Hark Kyun Kim; Il Ju Choi; Chan Gyoo Kim; Hee Sung Kim; Akira Oshima; Aleksandra Michalowski; Jeffrey E Green Journal: PLoS One Date: 2011-02-18 Impact factor: 3.240
Authors: Robert Sitarz; Małgorzata Skierucha; Jerzy Mielko; G Johan A Offerhaus; Ryszard Maciejewski; Wojciech P Polkowski Journal: Cancer Manag Res Date: 2018-02-07 Impact factor: 3.989
Authors: Kun Xu; Shenghui Sun; Mingjing Yan; Ju Cui; Yao Yang; Wenlin Li; Xiuqing Huang; Lin Dou; Beidong Chen; Weiqing Tang; Ming Lan; Jian Li; Tao Shen Journal: Front Oncol Date: 2022-08-03 Impact factor: 5.738